Spyros P Nikas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/25137/publications.pdf

Version: 2024-02-01

40 papers	1,408 citations	394421 19 h-index	345221 36 g-index
40 all docs	40 docs citations	40 times ranked	1721 citing authors

#	Article	IF	Citations
1	Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature, 2017, 547, 468-471.	27.8	379
2	Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures. Cell, 2020, 180, 655-665.e18.	28.9	212
3	CB1 Cannabinoid Receptor Ligands. Mini-Reviews in Medicinal Chemistry, 2005, 5, 631-640.	2.4	72
4	Cannabinoid Receptors as Therapeutic Targets. Current Pharmaceutical Design, 2006, 12, 1751-1769.	1.9	55
5	Novel 1â€²,1â€²-chain substituted Î”8-tetrahydrocannabinols. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3583-3586.	2.2	51
6	Pharmacophoric Requirements for the Cannabinoid Side Chain. Probing the Cannabinoid Receptor Subsite at C1â€˜. Journal of Medicinal Chemistry, 2003, 46, 3221-3229.	6.4	50
7	Novel 1â€²,1â€²-Chain Substituted Hexahydrocannabinols: 9Î²-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist. Journal of Medicinal Chemistry, 2010, 53, 6996-7010.	6.4	48
8	C1â€˜-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2007, 50, 4048-4060.	6.4	44
9	Sulfonyl Fluoride Inhibitors of Fatty Acid Amide Hydrolase. Journal of Medicinal Chemistry, 2012, 55, 10074-10089.	6.4	43
10	Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Molecular Pharmacology, 2019, 95, 155-168.	2.3	42
11	Fluorescent probes for G-protein-coupled receptor drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 933-947.	5.0	37
12	The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model. AAPS Journal, 2004, 6, 23-35.	4.4	35
13	Comparisons of Â9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 125-133.	2.5	33
14	Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Psychopharmacology, 2016, 233, 1879-1888.	3.1	29
15	Controlled-Deactivation Cannabinergic Ligands. Journal of Medicinal Chemistry, 2013, 56, 10142-10157.	6.4	26
16	Probing the Carboxyester Side Chain in Controlled Deactivation (â˜)-Î”⁸-Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2015, 58, 665-681.	6.4	26
17	13-Methylarachidonic Acid Is a Positive Allosteric Modulator of Endocannabinoid Oxygenation by Cyclooxygenase. Journal of Biological Chemistry, 2015, 290, 7897-7909.	3.4	25
18	3â€²-Functionalized Adamantyl Cannabinoid Receptor Probes. Journal of Medicinal Chemistry, 2015, 58, 3104-3116.	6.4	23

#	Article	IF	Citations
19	A concise methodology for the synthesis of (â^')-Î”9-tetrahydrocannabinol and (â^')-Î”9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs. Tetrahedron, 2007, 63, 8112-8123.	1.9	20
20	Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. Journal of Medicinal Chemistry, 2016, 59, 6903-6919.	6.4	20
21	A New Ring-Forming Methodology for the Synthesis of Conformationally Constrained Bioactive Molecules. Chemistry Letters, 2001, 30, 192-193.	1.3	16
22	(R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry, 2018, 61, 8639-8657.	6.4	12
23	Design and Synthesis of (13S)â€Methylâ€Substituted Arachidonic Acid Analogues: Templates for Novel Endocannabinoids. Chemistry - A European Journal, 2010, 16, 4091-4099.	3.3	11
24	C-Ring Cannabinoid Lactones: A Novel Cannabinergic Chemotype. ACS Medicinal Chemistry Letters, 2014, 5, 400-404.	2.8	11
25	Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Letters, 2015, 56, 1411-1415.	1.4	10
26	Cannabinoid CB₁ Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 314-323.	2.5	8
27	Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression. Cannabis and Cannabinoid Research, 2021, 6, 401-412.	2.9	8
28	Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. Journal of Medicinal Chemistry, 2021, 64, 3870-3884.	6.4	8
29	C1â€²-Azacycloalkyl Hexahydrocannabinols. Journal of Organic Chemistry, 2017, 82, 7839-7849.	3.2	7
30	Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 119-127.	2.5	7
31	Enantioselective synthesis of (10S)- and (10R)-methyl-anandamides. Tetrahedron, 2012, 68, 6329-6337.	1.9	6
32	Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure. Pharmaceuticals, 2018, 11, 50.	3.8	6
33	Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor. Molecules, 2019, 24, 3559.	3.8	5
34	Synthesis of Functionalized Cannabilactones. Molecules, 2020, 25, 684.	3.8	5
35	Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression. Cannabis and Cannabinoid Research, 2021, , .	2.9	5
36	Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 462-468.	2.5	4

#	Article	IF	Citations
37	Novel tail and head group prostamide probes. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1228-1231.	2.2	3
38	Oxa-adamantyl cannabinoids. Bioorganic and Medicinal Chemistry Letters, 2021, 38, 127882.	2.2	3
39	Targeting the Endocannabinoid System for Neuroprotection: A F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA. Journal of Pharmaceutics & Pharmacology, 2013, 1, .	0.5	2
40	Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists. European Journal of Medicinal Chemistry, 2022, 230, 114027.	5.5	1